Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $15.5 million.

  • Entrada Therapeutics' Accumulated Expenses rose 15.88% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 15.88%. This contributed to the annual value of $13.3 million for FY2024, which is 17.82% up from last year.
  • Latest data reveals that Entrada Therapeutics reported Accumulated Expenses of $15.5 million as of Q3 2025, which was up 31.68% from $11.8 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Accumulated Expenses registered a high of $15.5 million during Q3 2025, and its lowest value of $4.5 million during Q1 2022.
  • Over the past 3 years, Entrada Therapeutics' median Accumulated Expenses value was $11.3 million (recorded in 2023), while the average stood at $11.0 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 158.09% in 2023, then dropped by 24.70% in 2024.
  • Over the past 4 years, Entrada Therapeutics' Accumulated Expenses (Quarterly) stood at $7.6 million in 2022, then spiked by 49.49% to $11.3 million in 2023, then climbed by 17.82% to $13.3 million in 2024, then increased by 15.88% to $15.5 million in 2025.
  • Its last three reported values are $15.5 million in Q3 2025, $11.8 million for Q2 2025, and $7.6 million during Q1 2025.